| Market Cap | 6.62B | P/E | - | EPS this Y | -17.00% | Ern Qtrly Grth | - |
| Income | -456M | Forward P/E | 14.01 | EPS next Y | 39.80% | 50D Avg Chg | -2.00% |
| Sales | 4.5B | PEG | 15.36 | EPS past 5Y | - | 200D Avg Chg | 11.00% |
| Dividend | N/A | Price/Book | 0.95 | EPS next 5Y | 1.50% | 52W High Chg | -14.00% |
| Recommedations | 1.00 | Quick Ratio | 0.77 | Shares Outstanding | 351.90M | 52W Low Chg | 48.00% |
| Insider Own | 88.50% | ROA | 0.96% | Shares Float | 40.96M | Beta | 0.46 |
| Inst Own | 11.74% | ROE | -6.50% | Shares Shorted/Prior | 2.20M/1.91M | Price | 18.91 |
| Gross Margin | 60.85% | Profit Margin | -10.15% | Avg. Volume | 494,900 | Target Price | 27.05 |
| Oper. Margin | 3.04% | Earnings Date | Jul 31 | Volume | 1,023,819 | Change | -2.27% |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
| Evercore ISI Group | In-Line | Oct 1, 24 |
| HC Wainwright & Co. | Buy | Sep 23, 24 |
| Stifel | Hold | Sep 23, 24 |
| Needham | Hold | Sep 16, 24 |
| RBC Capital | Outperform | Aug 5, 24 |
| HC Wainwright & Co. | Buy | Aug 5, 24 |
| Deutsche Bank | Hold | Aug 1, 24 |
| RBC Capital | Outperform | Aug 1, 24 |
| Needham | Hold | Aug 1, 24 |